| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | KXQ762CQTH |
| InChI Key | BLQYVHBZHAISJM-CMDGGOBGSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C21H25N7 |
| Molecular Weight | 375.48 |
| AlogP | 3.17 |
| Hydrogen Bond Acceptor | 6.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 72.97 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 28.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Fibroblast growth factor receptor 3 inhibitor |
| Primary Target | |
|---|---|
| aurora kinase A | |
| fms related receptor tyrosine kinase 3 | |
| kinase insert domain receptor | |
| platelet derived growth factor receptor alpha | |
| protein tyrosine kinase 2 | |
| SRC proto-oncogene, non-receptor tyrosine kinase |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Adenocarcinoma, Clear Cell | 2 | D018262 | ClinicalTrials |
| Peritoneal Neoplasms | 2 | D010534 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
| Carcinoma, Hepatocellular | 2 | D006528 | ClinicalTrials |
| Sarcoma | 2 | D012509 | ClinicalTrials |
| Fallopian Tube Neoplasms | 2 | D005185 | ClinicalTrials |
| Multiple Myeloma | 1 | D009101 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Hematologic Neoplasms | 1 | D019337 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL482968 |
| DrugBank | DB16891 |
| EPA CompTox | DTXSID60239430 |
| FDA SRS | KXQ762CQTH |
| Guide to Pharmacology | 7885 |
| PDB | J3A |
| PubChem | 16041424 |
| SureChEMBL | SCHEMBL596481 |
| ZINC | ZINC000034885047 |